Literature DB >> 18356163

Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation.

Claire E McCoy1, Susan Carpenter, Eva M Pålsson-McDermott, Linden J Gearing, Luke A J O'Neill.   

Abstract

Phosphorylation of the transcription factor interferon regulatory factor 3 (IRF3) is essential for the induction of promoters which contain the interferon-stimulated response element (ISRE). IRF3 can be activated by Toll-like receptor 3 (TLR3) in response to the double-stranded RNA mimic poly(I-C) and by TLR4 in response to lipopolysaccharide (LPS). Here we have analyzed the effect of the glucocorticoid dexamethasone on this response. Dexamethasone inhibited the induction of the ISRE-dependent gene RANTES (regulated on activation normal T cell expressed and secreted) in both U373-CD14 cells and human peripheral blood mononuclear cells and also an ISRE luciferase construct, activated by either TLR3 or TLR4. It also inhibited increased phosphorylation of IRF3 in its N terminus in response to LPS and in its C terminus on Ser-396 in response to either poly(I-C) or LPS. Several dexamethasone-induced phosphatases were tested for possible involvement in these effects; MKP1 did not appear to be involved, although MKP2 and MKP5 both partially inhibited induction of the ISRE, pointing to their possible involvement in the effect of dexamethasone. Importantly, we found that dexamethasone could inhibit TBK1 kinase activity and TBK1 phosphorylation on Ser-172, both of which are required for IRF3 phosphorylation downstream of TLR3 and TLR4 stimulation. Our study, therefore, demonstrates that TBK1 is a target for dexamethasone, common to both TLR3 and TLR4 signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356163     DOI: 10.1074/jbc.M709731200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Herpes simplex encephalitis in patients with cancer.

Authors:  Jerome J Graber; Marc K Rosenblum; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2011-06-03       Impact factor: 4.130

2.  IL-10 inhibits miR-155 induction by toll-like receptors.

Authors:  Claire E McCoy; Frederick J Sheedy; Joseph E Qualls; Sarah L Doyle; Susan R Quinn; Peter J Murray; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2010-04-30       Impact factor: 5.157

3.  A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3.

Authors:  Alexa C Robitaille; Mélissa K Mariani; Audray Fortin; Nathalie Grandvaux
Journal:  J Vis Exp       Date:  2016-01-24       Impact factor: 1.355

Review 4.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 5.  Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.

Authors:  Karolien De Bosscher; Guy Haegeman
Journal:  Mol Endocrinol       Date:  2008-12-18

Review 6.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

7.  In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis).

Authors:  Harminder S Dua; Ahmad Muneer Otri; Andrew Hopkinson; Imran Mohammed
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 8.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 9.  Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms.

Authors:  Jamie R Flammer; Inez Rogatsky
Journal:  Mol Endocrinol       Date:  2011-04-21

10.  The type I interferon signaling pathway is a target for glucocorticoid inhibition.

Authors:  Jamie R Flammer; Jana Dobrovolna; Megan A Kennedy; Yurii Chinenov; Christopher K Glass; Lionel B Ivashkiv; Inez Rogatsky
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.